REDDITUX

This brand name is authorized in Turkey, South Africa

Active ingredients

The drug REDDITUX contains one active pharmaceutical ingredient (API):

1 Rituximab UNII 4F4X42SYQ6 - RITUXIMAB

Rituximab binds specifically to the transmembrane antigen, CD20, a non-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes. The antigen is expressed on >95% of all B cell non-Hodgkin’s lymphomas. Read about Rituximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REDDITUX Concentrate for solution for infusion	Health Products Regulatory Authority (ZA)	MPI, Generic

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FA01	Rituximab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FA CD20 (Clusters of Differentiation 20) inhibitors
Discover more medicines within L01FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680885576016, 8680885576023
Country: ZA	Health Products Regulatory Authority	Identifier(s): 56/26/0286, 56/26/0287